Search Within

Center for Hematologic Malignancies

Formats
  1. Journal Article (6195)
  2. Meeting Abstract (6166)
  3. Review (401)
  4. Book Section (216)
  5. Editorial (172)
  6. Research Letter (160)
  7. Guidelines (83)
  8. Conference Paper (70)
  9. Correspondence (61)
  10. Miscellaneous (19)
  11. Book Whole (10)
Groups
  1. Department of Medicine (11094)
  2. Hematologic Malignancies, Division of (10645)
  3. GSK Faculty (5449)
  4. Adult Leukemia (3723)
  5. Sloan Kettering Institute Faculty (3375)
  6. Hematologic Malignancies Research (3005)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (946)
  3. Ross Levine (787)
  4. Andrew Zelenetz (785)
  5. Steven Horwitz (671)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (317)
  2. 2024 (704)
  3. 2023 (877)
  4. 2022 (830)
  5. 2021 (802)
  6. 2020 (874)

More Years

Publications
  1. Blood (3413)
  2. Journal of Clinical Oncology (869)
  3. Biology of Blood and Marrow Transplantation (602)
  4. Clinical Lymphoma, Myeloma and Leukemia (304)
  5. Cancer Research (300)
  6. Haematologica (268)

More Publications

Publishers
  1. American Society of Hematology (3684)
  2. Elsevier Inc. (1669)
  3. Nature Publishing Group (1118)
  4. American Society of Clinical Oncology (918)
  5. American Association for Cancer Research (680)
  6. Wiley Blackwell (437)

More Publishers

Results (13553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1
    Meeting Abstract

    Jakubowiak, A. J.; Bahlis, N. J.; Raje, N. S.; Costello, C.; Dholaria, B. R.; Solh, M. M.; Levy, M. Y.; Tomasson, M. H.; Dube, H.; Damore, M. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Ghataorhe, P.; McKeown, A.; He, W.; Ling, T.; Jewell, R. C.; Byrne, J.; Eliason, L.; Scott, E. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study
    Meeting Abstract

    Hogan, L. E.; Bhatla, T.; Teachey, D. T.; Sirvent, F. J. B.; Moppett, J.; Puyó, P. V.; Micalizzi, C.; R?Ssig, C. R.; Shukla, N.; Gilad, G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Impact of a shared-care model between community and academic centers for facilitating access to allogeneic and autologous stem cell transplantation
    Meeting Abstract

    Fein, J. A.; McAuliffe, A.; Fischer, K.; Brady, O.; Devlin, S. M.; Willumsen, S.; Ozcan, G.; Montanaro, P.; Pristyazhnyuk, Y.; Digiuseppe, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Disparities in speed to BMT consult and allograft in 279 adults with AML
    Meeting Abstract

    Fingrut, W. B.; Gyurkocza, B.; Davis, E.; Flynn, J.; Scaradavou, A.; Chinapen, S.; Naputo, K.; Quach, S.; Cho, C.; Giralt, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Yabe, M.; Petrova-Drus, K.; Rosenblum, M.; Rotemberg, V.; Lacouture, M. E.; Rampal, R.; Francis, J.; Knoerzer, D.; Kreider, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial
    Meeting Abstract

    De Botton, S.; Risueño, A.; Schuh, A. C.; Lowenberg, B.; Kim, H. J.; Vyas, P.; Wei, A. H.; Stein, E. M.; Dohner, H.; Fathi, A. T.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Bosutinib (BOS) in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, effusion, and renal safety characterization in the BFORE trial
    Meeting Abstract

    Cortes, J. E.; Milojkovic, D.; Gambacorti-Passerini, C.; García-Gutierrez, V.; Mauro, M. J.; Leip, E.; Purcell, S.; Viqueira, A.; Brümmendorf, T. H.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical efficacy of daratumumab (DARA)-based second line therapy after DARAcontaining and DARA-free induction therapies in multiple myeloma: A single center experience
    Meeting Abstract

    Ciardiello, A.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Lu, S. X.; Patel, D.; Maclachlan, K.; Lahoud, O. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Patient preferences for second-line treatment options in diffuse large B-cell lymphoma: A discrete choice experiment
    Meeting Abstract

    Birch, K.; Chiu, K.; Baumgardner, J.; Snider, J.; Wade, S. W.; Shah, G. L.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save